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1.44 (0.28) to 1-79 (0.27) in the abdominal aorta, and from 0 93 (0.17) to 1-05 (0.19) in the umbilical artery; the volumetric blood flow in the umbilical vein decreased from 106 (28.8) to 84 (22.6) ml/min/kg. No such changes were seen after treatment with pindolol. Birth weight was similar in the two groups but placental weight was significantly different (529 (122) g in atenolol group v 653 (136) g in pindolol group; p=0 03).
Conclusion-The hypotensive effect was similar with both drugs, but only the 13 blocker atenolol had significant effects on fetal haemodynamics, although within normal ranges. The implications of these findings can be only speculative, but negative fetal consequences of 1 adrenoceptor blockade cannot be excluded.
Introduction 13 Adrenoceptor blockers have been widely used for treating hypertension in pregnancy. One of the most investigated drugs, the cardioselective 1P1 blocker atenolol, was reported in previous placebo controlled studies to have no adverse effects on fetal outcome.'`3 Recent studies, however, have raised concerns about possible negative influence on uteroplacental and fetal haemodynamics of cardioselective and non-selective 13 blockers. The PI blocker metoprolol and non-selective 13 blocker propranolol were shown to adversely affect fetal circulation in pregnant ewes after experimental asphyxia.45 Furthermore, in pregnant women with hypertension in the third trimester, atenolol increased fetal and uteroplacental peripheral vascular resistance. 6 A few studies on 13 blockers with intrinsic sympathomimetic activity, such as pindolol,7 and with cc, blocking activity, such as labetalol,8 using a gammacamera have suggested that they produce little change of uteroplacental blood flow. We compared two j3 blockers with different actions, atenolol and pindolol.
We studied maternal as well as fetal haemodynamics in women with pregnancy induced hypertension by using Doppler ultrasonography.
Patients and methods
The study included 32 women who were normotensive in the first trimnester and who were admitted to our hospitals with pregnancy induced hypertension (blood pressure 140/90 mm Hg or more on two occasions four hours or more apart). Women who had sustained hypertension after three days' rest in hospital, who met none of the exclusion criteria, and who agreed to participate in the study after being given oral and written information were included. The mean gestational age at admission was 35 (range 33-38) completed weeks. Exclusion criteria were multiple gestation, diastolic blood pressure 110 mm Hg or more, estimated fetal weight deviation of more than -22% (2 SD from estimated mean weight for gestational age), gestational age at recruitment less than 32 weeks, other drug treatment, contraindications to prolonging the pregnancy, or giving P blockers. The women were randomly allocated to antihypertensive treatment with either atenolol or pindolol. A double blind double dummy technique was used to allocate the antihypertensive drugs. Information on which treatment the women were given was stored in sealed envelopes and these were not opened until the study was completed. Two patients in the atenolol group had only one blood flow velocity measurement and were excluded; one was delivered within one week and the other rejected further participation in the study. One patient in the pindolol group was excluded because of side effects (tachycardia). Thus 29 patients participated in the study: 13 in the atenolol group and 16 in the pindolol group.
All pregnancies were dated by ultrasound measurement of the fetal biparietal diameter in the first half of gestation. Before women were entered into the study, fetal weight was estimated from the biparietal diameter and the mean abdominal diameter.9 None of the fetuses was small for gestational age-that is, with weight more than 2 SD below the mean. Seven women had proteinuria (three in the atenolol group and four in the pindolol group).
Bedrest and limited activity was advised during the first three days in hospital. Blood pressure was measured four times daily with the patient in a semirecumbent position by a mercury sphygmomanometer with appropriate cuff. Korotkoff phase 5 was used as an indicator of diastolic blood pressure. Mean arterial blood pressure (diastolic pressure+(systolic pressure-diastolic pressure)/3) was calculated and maternal heart rate was counted at each blood pressure recording. Electronic monitoring of fetal heart rate, fetal movements, and uterine contractions (non-stress test) was direction. Blood velocity (V) was recorded for at least 15 seconds in steady state, avoiding periods of fetal breathing and vigorous body movement. Vessel cross sectional area (A) was calculated from the mean value of 10 vessel diameters measured on 10 frozen real time images. The volumetric blood flow (Q) in the fetal thoracic descending aorta and the intra-abdominal part of the umbilical vein was calculated according to the formula Q=VxA/cos 45°. Blood flow was related to fetal weight, estimated from the ultrasonically measured biparietal and abdominal diameters,9 and expressed in ml/min/kg. The waveforms of the maximum velocity curves recorded from the descending aorta, the umbilical artery, and the maternal arcuate artery were characterised by the pulsatility index. Blood flow was measured twice, once before antihypertensive treatment and once on the seventh day of treatment. All ultrasound measurements were done at 11 00 am under standardised conditions at the Ultrasound Blood Flow Laboratory in Malmo.
The main measures of outcome were maternal blood pressure, maternal and fetal heart rate, blood velocity waveforms in fetal aorta and umbilical artery, and umbilical venous blood flow. For each haemodynamic parameter the difference (during treatment-before treatment) was used as the effect variable and compared between treatment groups. We calculated that with 15 patients in each group there was an 80% probability of detecting a difference between groups of at least 106% of the standard deviation of the differences. For the umbilical artery pulsatility index we estimated a standard deviation of 0-15 and a detectable difference of about 0-16. For the aortal pulsatility indices we estimated a standard deviation of 0 25 and a detectable difference of about 0-27.
A change in heart rate has been shown to influence the pulsatility index in the fetal descending aorta, maternal heart artery, and the arcuate artery. In our study a significant decrease in the fetal and maternal heart rate occurred during treatment, which might give a higher pulsatility index without the peripheral resistance having changed. Therefore the pulsatility index was always corrected for the heart rate-that is, it was normalised for a standard heart rate, according to reference values of our laboratory.'" 12
The study was approved by the local ethics committee of the University of Lund. All women gave their informed consent. Statistical evaluation was done within the groups by t tests for paired observations and between the groups by unpaired t test. Fisher's exact test was used to evaluate differences in fetal outcome. A p value less than 0-05 was considered significant.
Results Table I shows the characteristics of the women in the two groups. The mean duration of antihypertensive treatment did not differ between the atenolol and pindolol groups. Maternal mean arterial blood pressure was reduced after treatment by 9-0 (95% confidence interval -13-0 to -5 0) mm Hg in the atenolol group and by 7-8 (-11-4 to -4-2) mm Hg in the pindolol group (table II) . Maternal heart rate decreased in the atenolol group but was not altered in the pindolol group. Pulsatility index in the arcuate artery increased, though non-significantly, during treatment with atenolol (table II) .
On average, 18 to 19 non-stress tests (range 9-33) were performed in each woman. A significant reduction in fetal heart rate was observed in women who received atenolol (table III) . The volumetric blood flow did not change in the fetal aorta in either group. The umbilical venous blood flow, however, decreased significantly with atenolol, but slightly increased with pindolol (table III). BMJ VOLUME 304 11 APRIL 1992 The pulsatility index increased during atenolol treatment in fetal thoracic and abdominal aorta and in the umbilical artery. In contrast, during pindolol treatment the pulsatility index in the fetal blood vessels remained unchanged (table III) . Five patients in each group had ominous changes in fetal heart during labour. Table IV No serious side effects were observed during treatment with the two 3blockers, and the drugs were well tolerated by the patients.
Discussion
Atenolol and pindolol lowered the blood pressure in women with pregnancy induced hypertension. A significant decrease in both maternal and fetal heart rate was seen in the atenolol group but not in the pindolol group, confirming previous findings.' 6 The most important findings were, however, that the pulsatility index and consequently the peripheral vascular resistance increased consistently in the fetal aorta and umbilical artery after atenolol treatment 
